Voyager Therapeutics (VYGR) Reports Q2 Loss of $0.37/Share

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.37), versus ($5.94) reported last year.

Voyager reported cash, cash equivalents and marketable securities of $204.0 million as of June 30, 2016. Voyager continues to expect to end 2016 with cash, cash equivalents and marketable securities of $160.0 million and that its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into 2019.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Cerebras Q1 EPS miss sends shares down 9% after-hours